Physician profile
Michael E Merhige
NPI 1902887128
$2,531.74
in general payments reported to CMS, 2019-2025
20 companies · $280 in 2025
The $280 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $75.83 · 2021: $411 · 2022: $467 · 2023: $564 · 2024: $342 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161 · Education: $25.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,160.54 |
| Education | $25.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $461.84 | 2021-2024 | Nexletol |
| Novartis Pharmaceuticals Corporation | $327.97 | 2019-2025 | Leqvio |
| E.R. Squibb & Sons, L.L.C. | $297.96 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $205.61 | 2022-2025 | |
| Amgen INC. | $188.22 | 2022-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $175.79 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.25 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $124.31 | 2019-2022 | |
| Astellas Pharma US INC | $101.51 | 2019 | |
| Baxter Healthcare | $70.35 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Regeneron Healthcare Solutions, INC. | $64.77 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $61.67 | 2019 | |
| Merck Sharp & Dohme LLC | $57.80 | 2021-2022 | |
| Biotronik INC. | $46.18 | 2023 | Biomonitor |
| Boston Scientific Corporation | $44.14 | 2025 | Watchman |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $41.13 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $29.44 | 2021-2025 | Lokelma |
| Edwards Lifesciences Corporation | $23.54 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.13 | 2023 | Lifevest |
| Amryt Pharma Holdings LTD | $21.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Merhige listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.